Literature DB >> 8099015

Antigen processing and presentation of human rhinovirus to CD4 T cells is facilitated by binding to cellular receptors for virus.

G Z Hastings1, M J Francis, D J Rowlands, B M Chain.   

Abstract

Human rhinovirus serotypes (HRV) fall into two distinct groups, major and minor, by virtue of their cell receptor-binding ability. In this study minor receptor-binding group viruses are demonstrated to bind directly to cells of the murine immune system, including lymphoid dendritic cells which act as antigen-presenting cells, although they do not produce a productive infection in murine cells. This binding is specific and can be blocked by other serotypes of minor-group HRV. Pre-treatment of HRV 1A, a minor-group virus, with HRV 1A-specific antibodies inhibited the cellular proliferation of murine virus primed T helper cells, whereas antibody treatment of HRV 15, a non-binding major serotype, gave no inhibition. The cell binding ability of minor-group HRV played a role in the overall immunogenicity of this virus group, which was shown to be enhanced compared to the immunogenicity of major-group viruses in mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099015     DOI: 10.1002/eji.1830230623

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.

Authors:  Guohua Yi; Xiongying Tu; Preeti Bharaj; Hua Guo; Junli Zhang; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

2.  Human Rhinovirus Diversity and Evolution: How Strange the Change from Major to Minor.

Authors:  Nicole Lewis-Rogers; Jon Seger; Frederick R Adler
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

3.  Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine.

Authors:  Christopher C Stobart; Jenna M Nosek; Martin L Moore
Journal:  Front Microbiol       Date:  2017-12-05       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.